Triglycerides: A reappraisal

Trends Cardiovasc Med. 2017 Aug;27(6):428-432. doi: 10.1016/j.tcm.2017.03.004. Epub 2017 Mar 21.

Abstract

Elevated cholesterol levels are clearly independently associated with adverse cardiovascular events. Another class of lipid particles, triglycerides, is also abundant in the human body and has been found in atherosclerotic plaques. Recent observational studies have demonstrated an association between elevated triglyceride levels and increased risk for future cardiovascular events. With this knowledge and the discovery of effective agents to lower triglyceride levels, the management of triglycerides is currently undergoing a renaissance. Unfortunately, no randomized, controlled clinical trials have been completed to date, proving that lowering triglycerides will reduce cardiovascular events. In this review we highlight some of the evidence that led to this stage and discuss the current data on pharmacologic intervention of triglyceride levels and the effect on clinical outcomes. Lastly, we want to give the reader insight on what the most recent lipid guidelines state about clinical triglyceride management, mention new pharmacological agents, and highlight the clinical evidence for safe and effective lowering of triglycerides levels with life style modification.

Keywords: Cardiovascular disease; Triglycerides.

Publication types

  • Review

MeSH terms

  • Biomarkers / blood
  • Cardiovascular Diseases / etiology
  • Cardiovascular Diseases / prevention & control*
  • Dyslipidemias / blood*
  • Dyslipidemias / complications
  • Dyslipidemias / drug therapy*
  • Humans
  • Hypolipidemic Agents / therapeutic use*
  • Risk Assessment
  • Risk Factors
  • Risk Reduction Behavior
  • Treatment Outcome
  • Triglycerides / blood*

Substances

  • Biomarkers
  • Hypolipidemic Agents
  • Triglycerides